Fibroblast growth factor-23 in early chronic kidney disease: Additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 7, 2010, Pages 1268-1276

  Evenepoel, Pieter ^a   Meijers, Björn ^a   Viaene, Liesbeth ^a   Bammens, Bert ^a   Claes, Kathleen ^a   Kuypers, Dirk ^a   Vanderschueren, Dirk ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; BIOLOGICAL MARKER; CALCITRIOL; FIBROBLAST GROWTH FACTOR; PTH PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; URINARY EXCRETION; AGED; BELGIUM; BLOOD; CHI SQUARE DISTRIBUTION; CHRONIC DISEASE; COMPLICATION; CROSS-SECTIONAL STUDY; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; URINE;

ADULT; AGED; BELGIUM; BIOLOGICAL MARKERS; CALCITRIOL; CALCIUM; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RISK ASSESSMENT; RISK FACTORS;

EID: 77954783380     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08241109     Document Type: Article

References (57)

1. Nemere I: The ins and outs of phosphate homeostasis. Kidney Int 72: 140-142, 2007
2. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, Sarro F, Valdivielso JM, Fernandez E: Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Nephrol Dial Transplant 22: 1171-1176, 2007
3. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
4. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
5. Berndt T, Kumar R: Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 69: 341-359, 2007
6. Liu S, Quarles LD: How fibroblast growth factor 23 works. J Am Soc Nephrol 18: 1637-1674, 2007
7. Shigematsu T, Kazama J, Yamamashita T, Fukumoto S, Hosova T, Gejyo FFM: Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004
8. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Bone Miner Res 19: 429-435, 2004
9. Liu S, Tang W, Zhou J, Stubbs J, Luo Q, Pi M, Quarles L: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006
10. Wetmore JB, Quarles LD: Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: Time for a paradigm shift? Nat Clin Pract Nephrol 5: 24-33, 2009
11. Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M, Larsson TE: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 22: 3202-3207, 2007
12. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 18: 2601-2608, 2007 (Pubitemid 47378877)
13. Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T: Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23: 435-440, 2005
14. Bouillon R, Van Herck E, Jans I, Tan BK, Van Baelen H, De Moor P: Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 30: 1731-1736, 1984
15. Bouillon R, De Moor P, Baggiolini EG, Uskokovic MR: A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin Chem 26: 562-567, 1980
16. Bouillon R, Coopmans W, Degroote DE, Radoux D, Eliard PH: Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 36: 271-276, 1990
17. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S201, 2003
18. Botev R, Mallie JP, Couchoud C, Schuck O, Fauvel JP, Wetzels JFM, Lee N, De Santo NG, Cirillo M: Estimating glomerular filtration rate: Cockcroft-Gault and modification of diet in renal disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol 4: 899-906, 2009
19. Hsu Cy, Chertow GM: Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant 17: 1419-1425, 2002
20. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, for the Cholesterol And Recurrent Events (CARE) Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2005
21. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M'rad MB, Jacquot C, Houillier P, Stengel B, Fouqueray B, the NephroTest Study Group: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20: 164-171, 2009
22. Gupta A, Kallenbach LR, Zasuwa G, Divine GW: Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 11: 330-334, 2000 (Pubitemid 30064856)
23. Zehnder D, Landray MJ, Wheeler DC, Fraser W, Blackwell L, Nuttall S, Hughes SV, Townend J, Ferro C, Baigent C, Hewison M: Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract 107: c109-c116, 2007
24. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y: Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7: 1193-1200, 2007 (Pubitemid 46643105)
25. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M: Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19: 615-623, 2008 (Pubitemid 351355405)
26. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E: Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006
27. Thumfart J, Jung S, Amasheh S, Kraemer S, Peters H, Sommer K, Biber J, Murer H, Meij I, Querfeld U, Wagner CA, Muller DN: Magnesium stimulates renal phosphate reabsorption. Am J Physiol Renal Physiol 295: F1126-F1133, 2008
28. Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ, Kumar R: Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 104: 11085-11090, 2007 (Pubitemid 47175230)
29. Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, Fordtran JS: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30: 753-759, 1986 (Pubitemid 17049596)
30. Xu H, Bai L, Collins JF, Ghishan FK: Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)2 vitamin D3. Am J Physiol Cell Physiol 282: C487-C493, 2002
31. Williams KB, DeLuca HF: Characterization of intestinal phosphate absorption using a novel in vivo method. Am J Physiol Endocrinol Metab 292: E1917-E1921, 2007
32. Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 289: F8-F28, 2005
33. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007 (Pubitemid 350224109)
34. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T: Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77: 211-218, 2010
35. Coburn JW, Popovtzer M, Massry SG, Kleeman CR: The physicochemical state and renal handling of divalent ions in chronic renal failure. Arch Int Med 124: 302-311, 1969
36. Coburn JW, Koppel MH, Brickman AS, Massry SG: Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 3: 264-272, 1973
37. Popovtzer MM, Schainuck LJ, Massry SG, Kleeman CR: Divalent ion excretion in chronic kidney disease: Relation to degree of renal insufficiency. Clin Sci 38: 297-307, 1970
38. Goodman WG, Quarles LD: Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. Kidney Int 74: 276-288, 2008
39. Slatopolsky E, Bricker NS: The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4: 141-145, 1973
40. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004 (Pubitemid 39031360)
41. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005 (Pubitemid 41725150)
42. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885, 2007 (Pubitemid 46762749)
43. Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, Wilson PW, Vaccarino V, Raggi P: Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 199: 424-431, 2008
44. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA: Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 20: 397-404, 2009
45. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: 10e-117, 2000
46. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20: 381-387, 2009
47. Ix JH, de Boer IH, Peralta CA, Adeney KL, Duprez DA, Jenny NS, Siscovick DS, Kestenbaum BR: Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 4: 609-615, 2009
48. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
49. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
50. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007
51. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F: Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18: 613-620, 2007 (Pubitemid 46193327)
52. Kovesdy CP, Kalantar-Zadeh K: Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 73: 1355-1363, 2008 (Pubitemid 351770491)
53. Ibels L, Alfrey AC, Haut L, Huffer WE: Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 298: 122-126, 1978
54. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP: Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1: 825-831, 2006
55. de Boer IH, Rue TC, Kestenbaum B: Serum phosphorus concentrations in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 53: 399-407, 2009
56. Burnett S-A, Gunawardene S, Bringhurst FR, Juppner H, Lee H, Finkelstein JS: Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196, 2006
57. Oliveira RB, Cancela ALE, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RMA: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD Therapy? Clin J Am Soc Nephrol 5: 286-291, 2010